Literature DB >> 15802927

Beta-endorphin ameliorates synovial cell hyperfunction in the collagen-induced arthritis rat model by specific downregulation of NF-kappa B activity.

Hongen Yin1, Fengchun Zhang, Mengxue Yu, Hong Cheng, Jiayou Lin, Yang Gao, Bing Han, Liping Zhu.   

Abstract

OBJECTIVES: To observe the multiple immunoregulating effects of beta-endorphin (beta-END) on synovium cells of collagen-induced arthritis (CIA) in rats and to determine whether the regulation involves the transcriptional factor-kappaB (NF-kappaB) signal pathway.
METHODS: CIA was induced in female Wistar rats by immunization with native bovine type-II collagen emulsified with complete Freund's adjuvant. Synovial cells in the knees of the CIA rats were cultivated, and the effects of beta-END, beta-END receptor inhibitor (naloxone, Nal) in proliferation and apoptosis of the synovial cells were assayed by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, flow cytometry, and DNA integrity, respectively. The effects of beta-END and Nal on mRNA expression of several cytokines in the synovial cells, including tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), IL-6, regulated upon activation normal T-cell expressed and secreted (RANTES), inducible nitric oxide synthase (iNOS), matrix metalloproteinase-2 (MMP-2) and MMP-9 were estimated by quantitative reverse transcription-polymerase chain reaction. Effects of beta-END and Nal on NF-kappaB activity were analyzed using luciferase gene reporter assays. The effects of beta-END and Nal on p65NF-kappaB expression of the synovial cells were examined using Western blot.
RESULTS: 75% of the rats were demonstrated to have established the CIA model successfully. beta-END was shown to exert multiple effects on synovial cells of CIA rats including decreased proliferation, induced apoptosis, and downregulation of TNF-alpha, IL-1beta, IL-6, RANTES, iNOS, MMP-2 and MMP-9 mRNA expression. beta-END seemed to play an immunoregulating role by downregulating the activity and expression of NF-kappaB. It was found that the beta-END receptor blockage could counteract all the effects.
CONCLUSIONS: beta-END ameliorates synovial cell functions of CIA rats through binding with receptors and downregulating the NF-kappaB signal pathway. This suggests that beta-END, by blocking the activity and expression of NF-kappaB, is a potential anti-inflammatory and anti-rheumatic agent against CIA. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15802927     DOI: 10.1159/000084828

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  3 in total

1.  Alpinia katsumadai H(AYATA) seed extract inhibit LPS-induced inflammation by induction of heme oxygenase-1 in RAW264.7 cells.

Authors:  Mee-Young Lee; Chang-Seob Seo; Jin-Ah Lee; In-Sik Shin; Su-Jeong Kim; HeyKyung Ha; Hyeun-Kyoo Shin
Journal:  Inflammation       Date:  2012-04       Impact factor: 4.092

Review 2.  Role of proopiomelanocortin-derived peptides and their receptors in the osteoarticular system: from basic to translational research.

Authors:  Markus Böhm; Susanne Grässel
Journal:  Endocr Rev       Date:  2012-06-26       Impact factor: 19.871

Review 3.  Pathogenesis of psoriasis in the "omic" era. Part I. Epidemiology, clinical manifestation, immunological and neuroendocrine disturbances.

Authors:  Dominik Samotij; Bogusław Nedoszytko; Joanna Bartosińska; Aleksandra Batycka-Baran; Rafał Czajkowski; Iwona T Dobrucki; Lawrence W Dobrucki; Magdalena Górecka-Sokołowska; Anna Janaszak-Jasienicka; Dorota Krasowska; Leszek Kalinowski; Marta Macieja-Stawczyk; Roman J Nowicki; Agnieszka Owczarczyk-Saczonek; Agata Płoska; Dorota Purzycka-Bohdan; Adrianna Radulska; Edyta Reszka; Anna Siekierzycka; Andrzej Słomiński; Radomir Słomiński; Marta Sobalska-Kwapis; Dominik Strapagiel; Aneta Szczerkowska-Dobosz; Justyna Szczęch; Michał Żmijewski; Adam Reich
Journal:  Postepy Dermatol Alergol       Date:  2020-05-05       Impact factor: 1.837

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.